)
Medistim (MEDI) investor relations material
Medistim Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved record sales of NOK 182.3 million in Q4 2025 (up 20.6% YoY) and full-year revenue of NOK 699.8 million (up 24.4%), driven by strong own product sales and growth in Americas and APAC, with EMEA showing moderate growth.
EBIT reached NOK 42.3 million in Q4 (up 63.8–64.0% YoY) and NOK 196.2 million for the year (up nearly 50%), with EBIT margins at 23.2% in Q4 and 28% for the year.
Board proposes a dividend of NOK 8.00 per share, totaling NOK 146.2 million.
Launched new INTUI software for MiraQ Cardiac system and advanced key clinical studies, including the SMARTFLOW RCT and PATENT study.
Opened direct sales office in Tokyo, Japan, effective March 2026, to capture distributor margin and drive growth.
Financial highlights
Gross margin improved to 80.2% in Q4 and up to 81.7% for the year, driven by direct sales and product mix.
Profit after tax for Q4 was NOK 38.1 million (up 78–79% YoY); full-year profit after tax was NOK 159.2 million (up 53.3%).
Earnings per share for 2025 was NOK 8.71 (diluted), up from NOK 5.67 in 2024.
Cash position at year-end was NOK 212.1 million, with positive net cash flow and no interest-bearing bank debt.
EBITDA margin for the year increased to 31.6% (from 27.7%).
Outlook and guidance
Targeting NOK 1 billion in sales within a few years, focusing on direct market expansion, product innovation, and converting flow-only markets to flow-and-imaging.
Anticipates continued growth in CABG and vascular markets, with margin improvements from automation and product upgrades.
Direct sales office in Japan expected to drive growth and positive EBIT margin after transition.
Inventory levels expected to decrease in 2026 as major component purchases are deferred to 2027.
Growth in Americas expected to moderate from 2025’s high levels but remain strong, especially in vascular segment.
- Growth to NOK 1 billion targeted via INTUI software, innovation, and global clinical validation.MEDI
CMD 20243 Feb 2026 - Record Q2 sales, margin recovery, and EMEA growth offset APAC headwinds.MEDI
Q2 20241 Feb 2026 - Q3 revenue up 7%, EBIT margin at 24%, strong Americas, and recurring sales at 73–75%.MEDI
Q3 202418 Jan 2026 - Record sales, stable profit, and new innovations set up for strong 2025 growth.MEDI
Q4 20241 Dec 2025 - Record Q1 with 35.7% revenue growth, 84.5% EBIT surge, and strong outlook as INTUI launches.MEDI
Q1 202526 Nov 2025 - Record H1 sales and profit growth, led by Americas, APAC, and new product launches.MEDI
Q2 202523 Nov 2025 - Record sales and EBIT growth, strong margins, and robust cash position amid global expansion.MEDI
Q3 202524 Oct 2025
Next Medistim earnings date
Next Medistim earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage